Skip to content
superstack
Draft entry. Written from the cited papers but not yet reviewed by a person. Check the references before relying on any claim.
Stimulant· Dopaminergic· Monoamine reuptake inhibitor

Ritalin

also Methylphenidate · Methylphenidate hydrochloride · Immediate-release methylphenidate · Ritalin IR

Ritalin tablets contain immediate-release methylphenidate hydrochloride, a prescription stimulant used for ADHD and narcolepsy. [1] ADHD efficacy is well supported, while its shorter delivery profile means that trial regimens often use multiple daily doses. [2][3] This page focuses on ordinary tablets, not the separate Ritalin LA formulation.

An established short-acting methylphenidate formulation; timing flexibility comes with repeated dosing and familiar stimulant risks.

2D chemical structure of Ritalin
C14H19NO2233.31 g/molCID 4158 ↗
Established7 papers · 1999–2026 · 5 journals · 4 in humans
  • meta-analysis
  • RCT
  • trial
  • observational
  • preclinical / case
  • review / patent / other
  • retracted
1999 · RCT · A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.2000 · clinical trial · Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.2001 · clinical trial · Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.2013 · review · Amphetamine, past and present--a pharmacological and clinical perspective.2018 · meta-analysis · Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.2025 · other · RITALIN® (methylphenidate hydrochloride) tablets, for oral use, CIIInitial U.S. Approval: 19552026 · other · CONCERTA® (methylphenidate hydrochloride) extended-release tablets, for oral use, CII Initial U.S. Approval: 2000
in its favour
  • + Well-supported ADHD symptom reduction
  • + Immediate-release dosing studied against longer-acting options
watch for
  • − Repeated daytime dosing in many trial regimens
  • − Appetite loss, insomnia and misuse potential

Overview

This entry concerns immediate-release Ritalin tablets. They contain the same active methylphenidate as Concerta but do not use its osmotic release system. The US tablet label includes ADHD and narcolepsy; the efficacy trials summarized here concern ADHD. [1][4]

In the 68-child formulation comparison, immediate-release methylphenidate three times daily and once-daily Concerta both improved behavior and schoolwork, with little difference on most outcomes and similar appetite and sleep effects. [3]

In a separate small Ritalin-versus-Adderall crossover, both drugs helped, but the tested Adderall doses produced longer effects on some measures. Unequal functional potency and intensive concurrent behavioral treatment limit any conclusion that one drug is universally better. [5]

Mechanism

Ritalin contains racemic threo-methylphenidate; its d-enantiomer is more pharmacologically active. It inhibits dopamine and noradrenaline reuptake, increasing catecholamine availability. It is not an amphetamine prodrug. [1][6]

Direct targetswhat the molecule itself binds or acts on
  • Dopamine transporter (DAT)blocks
    Reduces dopamine reuptake. [1]
    strong
  • Noradrenaline transporter (NET)blocks
    Reduces noradrenaline reuptake. [1]
    strong

Formulation

how the form changes blood levels

Immediate-release delivery produces earlier peaks and more fluctuation with repeated doses than Concerta. A later dose creates another absorption peak; this is different from the gradual delivery of an osmotic tablet. [7]

Dosing

as studied or commonly reported; not a recommendation

Doses below are what studies used or, where marked, what is commonly reported. None is a recommendation.

Oral

  • 5, 10 or 15 mg per dose (immediate-release methylphenidate)
    68 children aged 6–12 already taking methylphenidate; comparison with Concerta and placebo
    three times daily · 7 days per condition in a three-condition crossover
    human study[3]
  • 10 or 17.5 mg per dose (Ritalin)
    25 children with ADHD in a behavioral summer-treatment program; comparison with Adderall and placebo
    twice daily, at 7:45 am and 12:15 pm · 24 randomized treatment days within a 6-week crossover
    human study[5]
Form
Immediate-release methylphenidate hydrochloride tablets; PubChem fields describe methylphenidate itself. Ritalin LA is a distinct release formulation and is outside this page’s dosing and PK scope. [1]
Timing and food
The tablet label describes divided dosing, preferably before meals, and warns about late dosing when sleep is affected. [1]
Time to effect
The crossover trials measured effects during the same treatment day; repeated doses were used to cover later activities. [3][5]
Notes
These rows report pediatric trial dosing. They are not a universal dose range or a conversion schedule for Concerta or amphetamines. [3][5]

Pharmacokinetics

what the body does with it
Half-lifeAbout 3 hours in the adult immediate-release comparator reported in the Concerta label; elimination half-life is not the same as duration of clinical benefit. [4][7]
Time to peakAbout 2 hours after a 10 mg immediate-release tablet on average; substantial individual variation is reported. [1]
Peak levelApproximately 4.3 ± 2.3 ng/mL after a 10 mg tablet in the label’s PK data. [1]
BioavailabilityThe label reports absolute oral bioavailability of 22 ± 8% for the d-enantiomer and 5 ± 3% for the l-enantiomer. [1]
MetabolismPrimarily de-esterified to ritalinic acid, which has little or no pharmacologic activity. [1]
ExcretionWithin 48–96 hours, 78–97% of a dose is recovered in urine as metabolites; less than 1% is unchanged methylphenidate. [1]

Safety

risks and cautions, not medical advice

Common problems include appetite loss, insomnia and increased pulse or blood pressure. The US label carries a boxed warning for abuse, misuse and addiction. Serious cardiac disease, new psychotic or manic symptoms, circulation problems in fingers or toes, and reduced growth in children require clinical attention. Blood pressure, pulse, weight and pediatric growth are monitored during treatment. [1]

The tablet label also warns about rare priapism and glaucoma-related problems. Short dosing intervals do not remove the drug’s cardiovascular, psychiatric or misuse risks. [1]

Adverse effects
reported, not universal
  • Appetite loss, insomnia, abdominal discomfort, nervousness and increased pulse or blood pressure. [1]
Cautions
who should think twice
  • Monitor blood pressure, pulse and pediatric growth; review cardiac disease and manic or psychotic symptoms. [1]
  • Rare priapism, peripheral circulation problems and increased intraocular pressure are included in the label warnings. [1]
Limits of the evidence
what has not been shown
  • The comparative evidence is strongest for short-term ADHD symptom control. The 2018 network meta-analysis had insufficient data at 26 and 52 weeks, and most indirect comparisons had low or very low certainty. It does not establish cognitive enhancement in healthy people. [2]
  • The 68-child formulation comparison enrolled children already taking methylphenidate and included behavioral treatment; each treatment condition lasted only seven days. [3]

Interactions

documented pairs only, not exhaustive

MAO inhibitors are contraindicated during treatment and for 14 days after their discontinuation because of hypertensive crisis risk. Methylphenidate can oppose antihypertensive treatment; blood pressure needs monitoring. [1]

The Ritalin label additionally identifies halogenated anesthetics and dose changes during concurrent risperidone treatment as interactions requiring attention. [1]

  • any mao inhibitor
    avoid
    Contraindicated during MAOI treatment and within 14 days after discontinuation because of hypertensive crisis risk. [1]
  • any stimulant
    caution
    Additional stimulants may compound cardiovascular and sleep effects; combined dosing needs a specific clinical rationale. [1]

FAQ

Are Ritalin and Concerta different drugs?
They use the same active methylphenidate. Ritalin here means immediate-release tablets; Concerta uses extended osmotic release. Their milligram doses and time courses are not interchangeable without a formulation-specific prescribing plan. [1][4]

References

entry last reviewed 2026-09-21
  1. [1]
  2. [2]
  3. [3]
    Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE, Gnagy EM, Burrows-Maclean L et al.Pediatrics 2001clinical trial · humanPMID 11389303◌ unreviewed
  4. [4]
  5. [5]
    A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE, Aronoff HR, Midlam JK et al.Pediatrics 1999RCT · humanPMID 10103335◌ unreviewed
  6. [6]
    Amphetamine, past and present--a pharmacological and clinical perspective.
    Heal DJ, Smith SL, Gosden J et al.J Psychopharmacol 2013reviewPMID 23539642◌ unreviewed
  7. [7]
    Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB, Lindemulder B, Gupta SKJ Clin Pharmacol 2000clinical trial · humanPMID 10761165◌ unreviewed